Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma

Int J Hematol. 2021 Jun;113(6):861-871. doi: 10.1007/s12185-021-03102-0. Epub 2021 Feb 16.

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma with a poor prognosis when treated with chemotherapy alone; therefore, allogeneic stem cell transplantation is a consideration. We attempted cord blood transplantation (CBT) using a reduced-intensity conditioning regimen without total body irradiation (non-TBI-RIC) to allow for the best possible timing of transplantation and improve survival outcomes, particularly in older patients. Forty-eight patients (27 male, 21 female) underwent CBT using fludarabine (Flu) 125 mg/m2 and melphalan (Mel) 140 mg/m2 as pre-transplant conditioning. The median age was 32 years (range 44-72), and 21 patients were in complete remission (CR) at the time of CBT. The median duration to neutrophil engraftment (NE) was 19.5 days (range 15-50), with a cumulative incidence of NE of 86.7% at day 50 after CBT. The 1- and 3-year overall survival (OS) rates were 40.4% and 37.7%, respectively. The 3-year OS rate in CR patients was 60.8%, compared with 18.8% in non-CR patients. In ATLL patients, CBT with non-TBI-RIC using Flu/Mel is a promising treatment strategy.

Keywords: Adult T-cell leukemia/lymphoma; Cord blood transplantation; Non-TBI regimen; Reduced-intensity regimen.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Allografts
  • Cord Blood Stem Cell Transplantation*
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / mortality*
  • Leukemia-Lymphoma, Adult T-Cell / therapy*
  • Male
  • Melphalan / administration & dosage*
  • Middle Aged
  • Survival Rate
  • Transplantation Conditioning*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*

Substances

  • Vidarabine
  • fludarabine
  • Melphalan